These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26901466)

  • 1. National Variation in Use of Immunosuppression for Kidney Transplantation: A Call for Evidence-Based Regimen Selection.
    Axelrod DA; Naik AS; Schnitzler MA; Segev DL; Dharnidharka VR; Brennan DC; Bae S; Chen J; Massie A; Lentine KL
    Am J Transplant; 2016 Aug; 16(8):2453-62. PubMed ID: 26901466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
    Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.
    Gatault P; Kamar N; Büchler M; Colosio C; Bertrand D; Durrbach A; Albano L; Rivalan J; Le Meur Y; Essig M; Bouvier N; Legendre C; Moulin B; Heng AE; Weestel PF; Sayegh J; Charpentier B; Rostaing L; Thervet E; Lebranchu Y
    Am J Transplant; 2017 May; 17(5):1370-1379. PubMed ID: 27862923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy.
    Sommerer C; Duerr M; Witzke O; Lehner F; Arns W; Kliem V; Ackermann D; Guba M; Jacobi J; Hauser IA; Stahl R; Reinke P; Rath T; Veit J; Mehrabi A; Porstner M; Budde K;
    Am J Transplant; 2018 Dec; 18(12):2965-2976. PubMed ID: 29722128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression.
    Nijhoff MF; Engelse MA; Dubbeld J; Braat AE; Ringers J; Roelen DL; van Erkel AR; Spijker HS; Bouwsma H; van der Boog PJ; de Fijter JW; Rabelink TJ; de Koning EJ
    Am J Transplant; 2016 Jan; 16(1):246-53. PubMed ID: 26288226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prednisone-free maintenance immunosuppression in obese kidney transplant recipients.
    Matas AJ; Vock DM
    Clin Transplant; 2019 Oct; 33(10):e13668. PubMed ID: 31310030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database.
    Tsai SF; Cheng CY; Shu KH; Wu MJ
    Transplant Proc; 2012 Jan; 44(1):190-2. PubMed ID: 22310612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
    Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
    Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study.
    Budde K; Lehner F; Sommerer C; Reinke P; Arns W; Eisenberger U; Wüthrich RP; Mühlfeld A; Heller K; Porstner M; Veit J; Paulus EM; Witzke O;
    Am J Transplant; 2015 Jan; 15(1):119-28. PubMed ID: 25521535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation.
    Kim J; Park J; Hwang S; Yoo H; Kim K; Park JB; Jang HR; Lee JE; Kim SJ; Kim YG; Kim DJ; Oh HY; Huh W
    Clin Transplant; 2018 Sep; 32(9):e13372. PubMed ID: 30080284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of sirolimus-based immunosuppression, fifteen years post-live-donor kidney transplantation: Single-center experience.
    Hamdy AF; Elhadedy MA; Donia AF; Taha NM; Bakr MA
    Clin Transplant; 2019 Feb; 33(2):e13463. PubMed ID: 30548935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone.
    Masterson R; Hughes P; Walker RG; Hogan C; Haeusler M; Robertson AR; Millar R; Suh N; Cohney SJ
    Am J Transplant; 2014 Dec; 14(12):2807-13. PubMed ID: 25389083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid-sparing maintenance immunosuppression is safe and effective after simultaneous liver-kidney transplantation.
    Weeks SR; Luo X; Toman L; Gurakar AO; Naqvi FF; Alqahtani SA; Philosophe B; Cameron AM; Desai NM; Ottmann SE; Segev DL; Garonzik-Wang J
    Clin Transplant; 2020 Oct; 34(10):e14036. PubMed ID: 32652700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus.
    Shihab F; Qazi Y; Mulgaonkar S; McCague K; Patel D; Peddi VR; Shaffer D
    Am J Transplant; 2017 Sep; 17(9):2363-2371. PubMed ID: 28141897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ; Yang HC; Holman MJ; Ahsan N
    J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation.
    Shuker N; Bouamar R; van Schaik RH; Clahsen-van Groningen MC; Damman J; Baan CC; van de Wetering J; Rowshani AT; Weimar W; van Gelder T; Hesselink DA
    Am J Transplant; 2016 Jul; 16(7):2085-96. PubMed ID: 26714287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.